Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 2019-03-01
A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended

2023-509576-42-00 Patients with resectable Non-small Cell Lung Cancer (St 2019-02-21
Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer Ended

2024-511144-86-00 Metastatic castration-resistant prostate cancer 2019-02-14
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 2019-02-11
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended

2023-510015-19-00 Patients with histologically or cytologically documente 2019-02-11
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 2019-02-01
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended

2024-513867-19-00 metastatic Castration-Resistant Prostate Cancer (mCRPC) 2019-01-31
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 2019-01-30
STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended

2024-516628-32-00 Multiple Sclerosis 2019-01-24
Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended

2024-511204-16-00 Metastatic breast cancer 2019-01-23
A Study of Zolbetuximab (IMAB362) plus CAPOX in Adults with Gastric Cancer. Ended

2024-511648-16-00 Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Adv 2019-01-04
Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Atopic Dermatitis 2019-01-02
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 2018-12-27
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Multiple Myeloma 2018-12-24
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Myelodysplastic syndrome (MDS) 2018-12-18
MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo… Ended

2022-500254-41-00 Stage III-IVA Resectable Locoregionally Advanced Head a 2018-12-13
A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri… Ended

2024-510976-19-00 Patients with Unresectable Locally Advanced or Metastat 2018-11-30
An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with… Ended

2023-508463-71-00 Newly Diagnosed Philadelphia Chromosome-Positive Acute 2018-11-30
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 High Risk Non-muscle invasive bladder cancer 2018-11-27
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 2018-11-27
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus… Ended

2024-511365-11-00 Metastatic Gastric or Gastroesophageal Junction (GEJ) A 2018-11-27
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Bas… Ended

2024-516662-11-00 Ovarian epithelial cancer 2018-11-23
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 2018-10-22
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 2018-10-18